AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31446437 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-Operator Cannulation Technology (SOCT) for ERCP
Number of subjects: 69
Study 31446437 — intervention group
Group type: COMPARATOR
Intervention: Regular ERCP procedure
Number of subjects: 69
Study 27580151 — intervention group
Group type: EXPERIMENTAL
Intervention: Calorie restriction (CR)
Number of subjects: 52
Study 27580151 — intervention group
Group type: EXPERIMENTAL
Intervention: Calorie restriction and exercise (CREX)
Number of subjects: 52
Study 27580151 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance exercise training (EX)
Number of subjects: 52
Study 27595142 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab (5 mg/kg intravenous infusion given over 2 h at baseline, and again at 2 weeks and 6 weeks after the first infusion)
Number of subjects: 270
Study 27595142 — intervention group
Group type: COMPARATOR
Intervention: Ciclosporin (2 mg/kg per day by continuous infusion for up to 7 days, followed by twice-daily tablets delivering 5.5 mg/kg per day for 12 weeks)
Number of subjects: 270
Study 27595142 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab
Number of subjects: 270
Study 27595142 — intervention group
Group type: COMPARATOR
Intervention: Ciclosporin
Number of subjects: 270
Study 25068741 — intervention group
Group type: EXPERIMENTAL
Intervention: Concept mapping (experimental group)
Number of subjects: 41
Study 25068741 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 41
Study 20881846 — intervention group
Group type: EXPERIMENTAL
Intervention: quetiapine XR (50-300 mg/day)
Number of subjects: 432
Study 20881846 — intervention group
Group type: EXPERIMENTAL
Intervention: quetiapine XR
Number of subjects: 432
Study 20881846 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 432
Study 19404190 — intervention group
Group type: EXPERIMENTAL
Intervention: Amantadine
Number of subjects: 7
Study 19404190 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 17301634 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy (CRT) with endurance training (ET)
Number of subjects: 17
Study 17301634 — intervention group
Group type: COMPARATOR
Intervention: Cardiac resynchronization therapy (CRT) without endurance training (ET)
Number of subjects: 17
Study 17301634 — intervention group
Group type: COMPARATOR
Intervention: Standard care with endurance training (ET)
Number of subjects: 17
Study 17301634 — intervention group
Group type: COMPARATOR
Intervention: Standard care only
Number of subjects: 17
Study 15008646 — intervention group
Group type: EXPERIMENTAL
Intervention: Competitive decision maker
Number of subjects: 0
Study 15008646 — intervention group
Group type: EXPERIMENTAL
Intervention: Prosocial value orientation
Number of subjects: 0
Study 15008646 — intervention group
Group type: EXPERIMENTAL
Intervention: Selfish value orientation
Number of subjects: 0
Study 15008646 — intervention group
Group type: EXPERIMENTAL
Intervention: Strategic misrepresentation
Number of subjects: 0
Study 11334128 — intervention group
Group type: EXPERIMENTAL
Intervention: PACQLQ intervention
Number of subjects: 62
Study 9879918 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive fluoride mouthrinsing (10 ml of 0.045% NaF neutral solution once a day for 3 days, twice a year, totaling 6 rinses per year)
Number of subjects: 139
Study 9879918 — intervention group
Group type: COMPARATOR
Intervention: Fluoride-free tap water rinsing (control group)
Number of subjects: 139
Study 9879918 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive fluoride mouthrinsing (among caries-free at baseline)
Number of subjects: 139
Study 9879918 — intervention group
Group type: COMPARATOR
Intervention: Fluoride-free tap water rinsing (among caries-free at baseline)
Number of subjects: 139
Study 7977190 — intervention group
Group type: EXPERIMENTAL
Intervention: Fränkel functional appliance
Number of subjects: 43
Study 7977190 — intervention group
Group type: COMPARATOR
Intervention: Headgear
Number of subjects: 43
Study 2525449 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinofibrate (200 mg, three times daily for 16 weeks)
Number of subjects: 20
Study 2525449 — intervention group
Group type: COMPARATOR
Intervention: Placebo (200 mg, three times daily for 16 weeks)
Number of subjects: 20
Study 29753264 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg dexamethasone
Number of subjects: 85
Study 29753264 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg dexamethasone
Number of subjects: 85
Study 29753264 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0 mg dexamethasone)
Number of subjects: 85
Study 25795409 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin plus gemcitabine (cisplatin 75 mg/m² on day 1 and gemcitabine 1250 mg/m² on days 1 and 8)
Number of subjects: 240
Study 25795409 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel plus gemcitabine (paclitaxel 175 mg/m² on day 1 and gemcitabine 1250 mg/m² on days 1 and 8)
Number of subjects: 240
Study 25795409 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin plus gemcitabine
Number of subjects: 240
Study 25795409 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel plus gemcitabine
Number of subjects: 240
Study 23816964 — intervention group
Group type: EXPERIMENTAL
Intervention: Abiraterone acetate (AA) plus prednisone (P)
Number of subjects: 1195
Study 23816964 — intervention group
Group type: COMPARATOR
Intervention: Prednisone (P) alone
Number of subjects: 1195
Study 20649689 — intervention group
Group type: EXPERIMENTAL
Intervention: CEE 0.625 mg/d with or without medroxyprogesterone acetate (MPA, 10 mg/d)
Number of subjects: 2304
Study 20649689 — intervention group
Group type: EXPERIMENTAL
Intervention: CEE alone therapy
Number of subjects: 2304
Study 20649689 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2304
Study 18250074 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-minute walk test (6MWT)
Number of subjects: 30
Study 18250074 — intervention group
Group type: EXPERIMENTAL
Intervention: Stroke Impact Scale (SIS) version 3.0 questionnaire
Number of subjects: 30
Study 18250074 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation analysis
Number of subjects: 30
Study 16608015 — intervention group
Group type: COMPARATOR
Intervention: QHBS in asymptomatic controls
Number of subjects: 28
Study 16608015 — intervention group
Group type: EXPERIMENTAL
Intervention: QHBS in SO stenosis group
Number of subjects: 28
Study 16608015 — intervention group
Group type: EXPERIMENTAL
Intervention: QHBS in SO dyskinesia group
Number of subjects: 28
Study 15363253 — intervention group
Group type: EXPERIMENTAL
Intervention: Portal vein chemotherapy (5‐fluorouracil infusion at 1g per day for 7 days after operation)
Number of subjects: 162
Study 15363253 — intervention group
Group type: COMPARATOR
Intervention: Intraluminal chemotherapy (5‐fluorouracil 0.5 g injected during operation)
Number of subjects: 162
Study 15363253 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 162
Study 11215556 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral nutritional supplementation (Group 1)
Number of subjects: 39
Study 11215556 — intervention group
Group type: COMPARATOR
Intervention: Normal unrestricted diet (Group 2)
Number of subjects: 39
Study 9024252 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant GH treatment for 9 months (adjusted for body surface area) in men
Number of subjects: 36
Study 9024252 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant GH treatment for 9 months (adjusted for body surface area) in women
Number of subjects: 36
Study 9024252 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant GH treatment for 9 months in men
Number of subjects: 36
Study 8274360 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral magnesium supplementation (366 mg Mg2+/d)
Number of subjects: 0
Study 8274360 — intervention group
Group type: COMPARATOR
Intervention: Pre-supplementation measurements
Number of subjects: 0
Study 3095501 — intervention group
Group type: EXPERIMENTAL
Intervention: Chex‐UP chemotherapy (four-drug combination: cyclophosphamide, hexamethylmelamine, 5‐fluorouracil, and cisplatin)
Number of subjects: 62
Study 3095501 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal (IP) 5‐FU (6 cycles)
Number of subjects: 62
Study 3095501 — intervention group
Group type: EXPERIMENTAL
Intervention: Chex‐UP chemotherapy
Number of subjects: 62
Study 29641631 — intervention group
Group type: EXPERIMENTAL
Intervention: Stabilization of the graft material with a fixed temporary appliance
Number of subjects: 0
Study 29641631 — intervention group
Group type: COMPARATOR
Intervention: No temporary reconstruction (control group)
Number of subjects: 0
Study 26340411 — intervention group
Group type: EXPERIMENTAL
Intervention: TEG-guided transfusion strategy
Number of subjects: 60
Study 26340411 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (SOC)
Number of subjects: 60
Study 24589454 — intervention group
Group type: EXPERIMENTAL
Intervention: IVD-A
Number of subjects: 1459
Study 24589454 — intervention group
Group type: EXPERIMENTAL
Intervention: IVD-B
Number of subjects: 1459
Study 24589454 — intervention group
Group type: COMPARATOR
Intervention: NSV
Number of subjects: 1459
Study 22933426 — intervention group
Group type: COMPARATOR
Intervention: NSAID use at baseline
Number of subjects: 160143
Study 22933426 — intervention group
Group type: EXPERIMENTAL
Intervention: NSAID use at both baseline and year 3
Number of subjects: 160143
Study 20113301 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal school-based group CBT (8 sessions)
Number of subjects: 56
Study 20113301 — intervention group
Group type: COMPARATOR
Intervention: No intervention (clinical control group)
Number of subjects: 56
Study 17928044 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention program focusing on the production of non-canonical sentences, specifically training in object-relative-clauses and who-questions.
Number of subjects: 7
Study 15890758 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate doses of training (3-6 months)
Number of subjects: 10
Study 15890758 — intervention group
Group type: EXPERIMENTAL
Intervention: Heavy doses of training (12 months)
Number of subjects: 10
Study 15890758 — intervention group
Group type: COMPARATOR
Intervention: Control group (Masters athletes aged 68 +/- 3 years and healthy sedentary young individuals aged 29 +/- 6 years)
Number of subjects: 10
Study 15890758 — intervention group
Group type: EXPERIMENTAL
Intervention: Training in seniors
Number of subjects: 10
Study 12807838 — intervention group
Group type: EXPERIMENTAL
Intervention: Bjork-Shiley prosthesis
Number of subjects: 533
Study 12807838 — intervention group
Group type: COMPARATOR
Intervention: Porcine prosthesis
Number of subjects: 533
Study 10830566 — intervention group
Group type: EXPERIMENTAL
Intervention: 20-week standard group continuing care intervention
Number of subjects: 127
Study 10830566 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized relapse prevention continuing care intervention
Number of subjects: 127
Study 10830566 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with APD
Number of subjects: 127
Study 10830566 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients without APD
Number of subjects: 127
Study 8798349 — intervention group
Group type: COMPARATOR
Intervention: Low-molecular-weight heparins (LMWH) alone (Group A: n = 591)
Number of subjects: 1372
Study 8798349 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Daflon 500 mg with LMWH (Group B: n = 595)
Number of subjects: 1372
Study 8798349 — intervention group
Group type: COMPARATOR
Intervention: Low-molecular-weight heparins (LMWH) alone (Group C: n = 93)
Number of subjects: 1372
Study 8798349 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Daflon 500 mg with LMWH (Group D: n = 93)
Number of subjects: 1372
Study 1458667 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.125% amorolfine cream
Number of subjects: 232
Study 1458667 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% amorolfine cream
Number of subjects: 232
Study 1458667 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% amorolfine cream
Number of subjects: 232
Study 1458667 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% bifonazole cream
Number of subjects: 232
Study 6085004 — intervention group
Group type: EXPERIMENTAL
Intervention: 9 beta-methyl carbacyclin
Number of subjects: 0
Study 6085004 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoprostenol
Number of subjects: 0
Study 6085004 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 6085004 — intervention group
Group type: EXPERIMENTAL
Intervention: 9 beta-methyl carbacyclin and Epoprostenol
Number of subjects: 0
Study 29663871 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation (15 mg for men; 12 mg for women)
Number of subjects: 254
Study 29663871 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 254
Study 27906432 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensity modulated radiotherapy (DT 50 Gy, 2.0 Gy/fraction, 25 times, during 33-35 days)
Number of subjects: 112
Study 27906432 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent radio chemotherapy and intensity modulated radiotherapy
Number of subjects: 112
Study 27906432 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent radio chemotherapy and hypofractionation (DT of 42.56 Gy, 2.66Gy/fraction, 16 times, during 22-24 days)
Number of subjects: 112
Study 23910578 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylaxis with FEIBA NF (85 ± 15 U kg(‐1) every other day)
Number of subjects: 36
Study 23910578 — intervention group
Group type: COMPARATOR
Intervention: On-demand treatment with FEIBA NF
Number of subjects: 36
Study 23910578 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylaxis with FEIBA NF
Number of subjects: 36
Study 22368077 — intervention group
Group type: EXPERIMENTAL
Intervention: No headrest
Number of subjects: 100
Study 22368077 — intervention group
Group type: COMPARATOR
Intervention: Headrest
Number of subjects: 100
Study 20493549 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril (2 mg, 4 mg, or 8 mg once daily)
Number of subjects: 0
Study 20493549 — intervention group
Group type: COMPARATOR
Intervention: Placebo (oral)
Number of subjects: 0
Study 19137769 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus ointment
Number of subjects: 0
Study 19137769 — intervention group
Group type: COMPARATOR
Intervention: Pimecrolimus cream
Number of subjects: 0
Study 15832627 — intervention group
Group type: EXPERIMENTAL
Intervention: Deeper processing during encoding (semantic, phonemic, or graphemic questions) for twice-presented items
Number of subjects: 0
Study 15832627 — intervention group
Group type: COMPARATOR
Intervention: Deeper processing during encoding (semantic, phonemic, or graphemic questions) for once-presented items
Number of subjects: 0
Study 12001553 — intervention group
Group type: EXPERIMENTAL
Intervention: Headgear Herbst appliance and step-by-step advancement (HHSSA)
Number of subjects: 45
Study 12001553 — intervention group
Group type: COMPARATOR
Intervention: Conventional Herbst appliance with maximal jumping (HMJ)
Number of subjects: 45
Study 10459591 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminophylline
Number of subjects: 82
Study 10459591 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study 7823996 — intervention group
Group type: EXPERIMENTAL
Intervention: Bed rest for two days
Number of subjects: 186
Study 7823996 — intervention group
Group type: EXPERIMENTAL
Intervention: Back-mobilizing exercises
Number of subjects: 186
Study 7823996 — intervention group
Group type: COMPARATOR
Intervention: Ordinary activities as tolerated (Control)
Number of subjects: 186
Study 2505712 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril 4 mg orally
Number of subjects: 0
Study 2505712 — intervention group
Group type: COMPARATOR
Intervention: Perindopril 2 mg orally
Number of subjects: 0
Study 2505712 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril 8 mg orally
Number of subjects: 0
Study 335203 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol
Number of subjects: 24
Study 335203 — intervention group
Group type: COMPARATOR
Intervention: Pindolol
Number of subjects: 24
Study 335203 — intervention group
Group type: COMPARATOR
Intervention: Alprenolol
Number of subjects: 24
Study 29446817 — intervention group
Group type: EXPERIMENTAL
Intervention: Depressed Type 2 diabetic patients (T2DP)
Number of subjects: 100
Study 29446817 — intervention group
Group type: EXPERIMENTAL
Intervention: Anxiety in Type 2 diabetic patients (T2DP)
Number of subjects: 100
Study 29446817 — intervention group
Group type: EXPERIMENTAL
Intervention: Anxious-depressive co-morbidity in Type 2 diabetic patients (T2DP)
Number of subjects: 100
Study 29446817 — intervention group
Group type: EXPERIMENTAL
Intervention: Mood disorders in Type 2 diabetic patients (T2DP)
Number of subjects: 100
Study 29446817 — intervention group
Group type: EXPERIMENTAL
Intervention: Dysthymia in Type 2 diabetic patients (T2DP)
Number of subjects: 100
Study 29446817 — intervention group
Group type: EXPERIMENTAL
Intervention: Isolated depressive episode in Type 2 diabetic patients (T2DP)
Number of subjects: 100
Study 29446817 — intervention group
Group type: COMPARATOR
Intervention: Glycemic control in depressed vs non-depressed Type 2 diabetic patients (T2DP)
Number of subjects: 100
Study 29446817 — intervention group
Group type: COMPARATOR
Intervention: Factors associated with depression in Type 2 diabetic patients (T2DP)
Number of subjects: 100
Study 25774559 — intervention group
Group type: EXPERIMENTAL
Intervention: Compliance Therapy (up to six weekly sessions)
Number of subjects: 18
Study 25774559 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control (standard care)
Number of subjects: 18
Study 23382960 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsaicin cream
Number of subjects: 25
Study 23382960 — intervention group
Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 25
Study 21314752 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release naltrexone (XR-NTX)
Number of subjects: 74
Study 19081418 — intervention group
Group type: EXPERIMENTAL
Intervention: ABT-335 + simvastatin 20 mg
Number of subjects: 657
Study 19081418 — intervention group
Group type: EXPERIMENTAL
Intervention: ABT-335 + simvastatin 40 mg
Number of subjects: 657
Study 19081418 — intervention group
Group type: COMPARATOR
Intervention: simvastatin 20 mg
Number of subjects: 657
Study 19081418 — intervention group
Group type: COMPARATOR
Intervention: simvastatin 40 mg
Number of subjects: 657
Study 19081418 — intervention group
Group type: COMPARATOR
Intervention: ABT-335 monotherapy (135 mg)
Number of subjects: 657
Study 17888840 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with reduced eGFR
Number of subjects: 603
Study 17888840 — intervention group
Group type: COMPARATOR
Intervention: Patients with normal renal function
Number of subjects: 603
Study 17888840 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline differences in LVMI
Number of subjects: 603
Study 17888840 — intervention group
Group type: EXPERIMENTAL
Intervention: LVMI and LA volume
Number of subjects: 603
Study 11093292 — intervention group
Group type: EXPERIMENTAL
Intervention: Short walks (10 min brisk walking before each meal)
Number of subjects: 10
Study 11093292 — intervention group
Group type: EXPERIMENTAL
Intervention: Long walk (30 min brisk walking before breakfast)
Number of subjects: 10
Study 11093292 — intervention group
Group type: COMPARATOR
Intervention: Control (no exercise)
Number of subjects: 10
Study 11093292 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking (combined short and long walks)
Number of subjects: 10
Study 8942424 — intervention group
Group type: EXPERIMENTAL
Intervention: 3,4-didehydroretinyl acetate (DRA) administered at standard doses: 5.3 mumol for children < 6 y, 7.0 mumol for children 6-12 y, 8.8 mumol for adults and children > 12 y.
Number of subjects: 84
Study 8942424 — intervention group
Group type: EXPERIMENTAL
Intervention: DRA in vitamin E-containing corn oil, with or without 4.6 mmol all-rac-alpha-tocopheryl acetate/L.
Number of subjects: 84
Study 8942424 — intervention group
Group type: EXPERIMENTAL
Intervention: DRA stored in amber glass vials.
Number of subjects: 84
Study 8942424 — intervention group
Group type: EXPERIMENTAL
Intervention: 3,4-didehydro-retinol to retino ratio.
Number of subjects: 84
Study 1848053 — intervention group
Group type: EXPERIMENTAL
Intervention: Towne live attenuated virus vaccine
Number of subjects: 237
Study 1848053 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 237
Study 6220334 — intervention group
Group type: EXPERIMENTAL
Intervention: Almitrine (60 mg/24 h)
Number of subjects: 30
Study 6220334 — intervention group
Group type: EXPERIMENTAL
Intervention: Duxil (5023 SE)
Number of subjects: 30
Study 6220334 — intervention group
Group type: COMPARATOR
Intervention: Raubasine (20 mg/24 h)
Number of subjects: 30
Study 31010346 — intervention group
Group type: EXPERIMENTAL
Intervention: Super Skin Rejuvenation (SSR) 540 nm
Number of subjects: 60
Study 31010346 — intervention group
Group type: EXPERIMENTAL
Intervention: Pixel Q-switched Nd: YAG (PQSNDY) 1064 nm
Number of subjects: 60
Study 31010346 — intervention group
Group type: EXPERIMENTAL
Intervention: Ablative pixel-Er: YAG (2940 nm)
Number of subjects: 60
Study 29324776 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Number of subjects: 577
Study 29324776 — intervention group
Group type: COMPARATOR
Intervention: Control (direct infertility treatment)
Number of subjects: 577
Study 26528775 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin 150 mg + placebo
Number of subjects: 12
Study 26528775 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil (highest TCI level)
Number of subjects: 12
Study 26528775 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin + Remifentanil (highest TCI level)
Number of subjects: 12
Study 26528775 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 26528775 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin
Number of subjects: 12
Study 26528775 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil
Number of subjects: 12
Study 26528775 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin + Remifentanil
Number of subjects: 12
Study 24656590 — intervention group
Group type: EXPERIMENTAL
Intervention: Intratendinous injection of platelet-rich plasma (PRP) under ultrasound (US) guidance
Number of subjects: 408
Study 22173883 — intervention group
Group type: EXPERIMENTAL
Intervention: Blue Dog software program
Number of subjects: 76
Study 22173883 — intervention group
Group type: COMPARATOR
Intervention: Fire safety software program
Number of subjects: 76